Article, Early Access,
Are insulin sensitizers the new strategy to treat Type 1 diabetes? A long-acting dual amylin and calcitonin receptor agonist improves insulin-mediated glycaemic control and controls body weight
Contributors
Melander, S. A.
0000-0002-1844-3294
(Corresponding author)
[1]
Larsen, Anna T.
0000-0002-3286-4319
[1]
Karsdal, Morten A.
0000-0001-5026-8740
[1]
[2]
Affiliations
- [1] NORD BIOSci, Herlev, Denmark [NORA names: Nordic Bioscience; Private Research; Denmark; Europe, EU; Nordic; OECD];
- [2] KeyBiosci AG, Stans, Switzerland [NORA names: Switzerland; Europe, Non-EU; OECD]
Abstract
Abstract not displayed. As this article is not marked as Open Access, it is unclear if we are allowed to show the abstract. Please use the link in the sidebar to view the data provider version of the article including abstract.
Keywords
DACRA,
combination therapy,
glycaemic control,
hyperglucagonomia,
insulin sensitivity,
insulin sensitizer,
type 1 diabetes
